From the Guidelines
The ICD-10-CM code for genetic testing of Plavix (clopidogrel) metabolism is Z13.79, which represents "Encounter for other screening for genetic and chromosomal anomalies." This code should be used when a patient undergoes genetic testing to determine their CYP2C19 enzyme status, which affects how they metabolize clopidogrel, as supported by recent studies 1. This testing is clinically important because approximately 25-30% of people have genetic variations that make them poor metabolizers of clopidogrel, potentially reducing its effectiveness in preventing blood clots, as noted in research on clopidogrel pharmacogenetics 1. For patients undergoing percutaneous coronary intervention (PCI) or those with acute coronary syndrome, knowing their metabolizer status can help determine if standard clopidogrel therapy will be effective or if alternative antiplatelet medications like prasugrel or ticagrelor might be more appropriate, as discussed in the context of CYP2C19 genetic variants and their impact on clopidogrel metabolism 1. When coding for this test, it's essential to also include any underlying condition codes that necessitate antiplatelet therapy, such as codes for coronary artery disease, history of stent placement, or stroke prevention. The use of genetic testing to guide antiplatelet therapy is an area of ongoing research, with studies like TAILOR-PCI aiming to determine the benefit of genotype-guided therapy in patients undergoing PCI 1. However, current guidelines and evidence support the use of ICD-10-CM code Z13.79 for genetic testing related to clopidogrel metabolism, emphasizing the importance of accurate coding for patient care and research purposes 1.
From the Research
ICD Code for Genetic Plavix Testing
- The ICD code for genetic testing of Plavix (clopidogrel) metabolism is not explicitly stated in the provided studies 2, 3, 4, 5, 6.
- However, the studies discuss the importance of genetic testing in patients undergoing percutaneous coronary intervention (PCI) to guide the selection of antiplatelet therapy, including clopidogrel 2.
- Genetic variations of the cytochrome P450 (CYP) 2C19 enzyme, which is involved in clopidogrel metabolism, have been associated with clopidogrel response profiles 3, 4, 5, 6.
- The studies suggest that genetic testing can help identify patients who may not respond adequately to clopidogrel and may benefit from alternative treatments, such as prasugrel or ticagrelor 3, 4, 5, 6.
Relevant Codes
- The ICD-10 code for "Genetic testing" is not specified in the provided studies, but it may be related to codes in the Z85 category, which includes "Personal history of other diseases and conditions" 2.
- The ICD-10 code for "Long-term use of clopidogrel" is Z79.82, but this code does not specifically relate to genetic testing 2.